Trial reportThorax2013
Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.
Trial report in Thorax, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 11 syntheses or guidelines pooled it, 244 citations in OpenAlex.
- Management of Adult Bronchiectasis: Consensus-Based Guidelines of the German Respiratory Society.Respiration; international review of thoracic diseases · 2026Guideline
- Pooled it
- Intermittent prophylactic antibiotics for bronchiectasis.The Cochrane database of systematic reviews · 2022Pooled it
- Psychometrics of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis.The European respiratory journal · 2021Pooled it
- A systematic review of pharmacotherapeutic clinical trial end-points for bronchiectasis in adults.European respiratory review : an official journal of the European Respiratory Society · 2019Pooled it
- Antibiotic therapy for stable non-CF bronchiectasis in adults - A systematic review.Chronic respiratory disease · 2017Pooled it
- Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults.The Cochrane database of systematic reviews · 2015Pooled it
- Interventions for bronchiectasis: an overview of Cochrane systematic reviews.The Cochrane database of systematic reviews · 2015Pooled it
- Bronchiectasis.BMJ clinical evidence · 2015Pooled it
- Efficacy of inhaled ciprofloxacin agents for the treatment of bronchiectasis: a systematic review and meta-analysis of randomized controlled trials.Therapeutic advances in respiratory diseasePooled it
- Inhaled antibiotics therapy for stable non-cystic fibrosis bronchiectasis: a meta-analysis.Therapeutic advances in respiratory diseasePooled it
- Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection.American journal of respiratory and critical care medicine · 2014Trial
- Systematic Review of Antimicrobial Therapies and Clinical Outcomes inLife (Basel, Switzerland) · 2026Review
- Inhaled Ciprofloxacin as an Alternative Treatment for Infection withAntibiotics (Basel, Switzerland) · 2026Article
- Inhalable Nanosystems for Bacterial Respiratory Infections: Addressing Pulmonary Barriers and Biofilm-Associated Challenges.International journal of nanomedicine · 2026Review
- Gelatin-Based Microspheres of Ciprofloxacin for Enhanced Lung Delivery and Biofilm Eradication inGels (Basel, Switzerland) · 2025Article
- Comparative efficacy and safety of inhaled antibiotics in managing chronicJournal of thoracic disease · 2025Article
- Utilization of Inhaled Antibiotics in Pediatric Non-Cystic Fibrosis Bronchiectasis: A Comprehensive Review.Antibiotics (Basel, Switzerland) · 2025Review
- Pulmonary Delivery of Antibiotics to the Lungs: Current State and Future Prospects.Pharmaceutics · 2025Review
- Brensocatib in patients with bronchiectasis: subgroup analyses from the WILLOW trial.ERJ open research · 2025Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe delivery of antipseudomonal antibiotics by inhalation to Pseudomonas aeruginosa-infected subjects with non-cystic fibrosis (CF) bronchiectasis is a logical extension of treatment strategies successfully developed in CF bronchiectasis. Dual release ciprofloxacin for inhalation (DRCFI) contains liposomal ciprofloxacin, formulated to optimise airway antibiotic delivery.
methodsPhase II, 24-week Australian/New Zealand multicentre, randomised, double-blind, placebo-controlled trial in 42 adult bronchiectasis subjects with ≥2 pulmonary exacerbations in the prior 12 months and ciprofloxacin-sensitive P aeruginosa at screening. Subjects received DRCFI or placebo in three treatment cycles of 28 days on/28 days off. The primary outcome was change in sputum P aeruginosa bacterial density to the end of treatment cycle 1 (day 28), analysed by modified intention to treat (mITT). Key secondary outcomes included safety and time to first pulmonary exacerbation-after reaching the pulmonary exacerbation endpoint subjects discontinued study drug although remained in the study.
resultsDRCFI resulted in a mean (SD) 4.2 (3.7) log10 CFU/g reduction in P aeruginosa bacterial density at day 28 (vs -0.08 (3.8) with placebo, p=0.002). DRCFI treatment delayed time to first pulmonary exacerbation (median 134 vs 58 days, p=0.057 mITT, p=0.046 per protocol). DRCFI was well tolerated with a similar incidence of systemic adverse events to the placebo group, but fewer pulmonary adverse events.
conclusionsOnce-daily inhaled DRCFI demonstrated potent antipseudomonal microbiological efficacy in adults with non-CF bronchiectasis and ciprofloxacin-sensitive P aeruginosa. In this modest-sized phase II study, DRCFI was also well tolerated and delayed time to first pulmonary exacerbation in the per protocol population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.